Abnormal Marrow Cellularity at Day 100 after Allogeneic Marrow Transplantation Impacts Overall Survival (OS) but Not Event-Free Survival (EFS)

被引：0
|
作者：
Sojitra, P. [1 ]
Gandhi, P. [1 ]
Kini, A. R. [1 ]
Velankar, M. M. [1 ]
Smith, S. [1 ]
Stiff, P. J. [1 ]
Venkataraman, G. [1 ]
机构：
[1] Loyola Univ, Med Ctr, Maywood, IL 60153 USA
来源：
MODERN PATHOLOGY | 2013年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
1516
引用
收藏
页码：362A / 362A
页数：1
相关论文
共 50 条
  • [1] Abnormal Marrow Cellularity at Day 100 after Allogeneic Marrow Transplantation Impacts Overall Survival (OS) but Not Event-Free Survival (EFS)
    Sojitra, P.
    Gandhi, P.
    Kini, A. R.
    Velankar, M. M.
    Smith, S.
    Stiff, P. J.
    Venkataraman, G.
    LABORATORY INVESTIGATION, 2013, 93 : 362A - 362A
  • [2] Marrow Hematogones as a Percent of B-Lymphocytes Correlates with Event-Free Survival (EFS) after Allogeneic Bone Marrow Transplant
    Sojitra, P.
    Hu, Z.
    Li, Y.
    Parthasarathy, M.
    Kini, A. R.
    Stiff, P. J.
    Venkataraman, G.
    LABORATORY INVESTIGATION, 2012, 92 : 371A - 372A
  • [3] Marrow Hematogones as a Percent of B-Lymphocytes Correlate's with Event-Free Survival (EFS) after Allogeneic Bone Marrow Transplant
    Sojitra, P.
    Hu, Z.
    Li, Y.
    Parthasarathy, M.
    Kini, A. R.
    Stiff, P. J.
    Venkataraman, G.
    MODERN PATHOLOGY, 2012, 25 : 371A - 372A
  • [4] EVALUATION OF OVERALL SURVIVAL (OS) AND EVENT-FREE SURVIVAL (EFS) OF PAEDIATRIC SARCOMA PATIENTS - WEST OF SCOTLAND EXPERIENCE
    Ronghe, M.
    Murphy, D.
    Sastry, J.
    Donnelly, P.
    Macdonald, A.
    Cowie, F.
    Jones, R.
    Duncan, R.
    PEDIATRIC BLOOD & CANCER, 2014, 61 : S275 - S275
  • [5] Preemptive Bone Marrow Transplantation and Event-Free Survival in Fanconi Anemia
    Khan, Nicholas E.
    Rosenberg, Philip S.
    Alter, Blanche P.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (10) : 1888 - 1892
  • [6] Event-free survival (EFS) and overall survival (OS) of MYCN-amplified stage 2/3 neuroblastoma with or without autologous stem-cell transplantation (ASCT).
    Kushner, Brian H.
    Modak, Shakeel
    LaQuaglia, Michael P.
    Wolden, Suzanne L.
    Basu, Ellen M.
    Roberts, Stephen S.
    Kramer, Kim
    Cheung, Irene Y.
    Cheung, Nai-Kong V.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] Aberrant T-Cell Antigen Expression in Classical Hodgkin Lymphoma Is Associated with Decreased Event-Free Survival (EFS) and Overall Survival (OS)
    Venkataraman, G.
    Traverse-Glehen, A.
    Song, J. Y.
    Eberle, F. C.
    Hanson, J. C.
    Dirnhofer, S.
    Tzankov, A.
    Heinze, G.
    Raffeld, M. A.
    Pittaluga, S.
    Jaffe, E. S.
    LABORATORY INVESTIGATION, 2011, 91 : 326A - 327A
  • [8] Aberrant T-Cell Antigen Expression in Classical Hodgkin Lymphoma Is Associated with Decreased Event-Free Survival (EFS) and Overall Survival (OS)
    Venkataraman, G.
    Traverse-Glehen, A.
    Song, J. Y.
    Eberle, F. C.
    Hanson, J. C.
    Dirnhofer, S.
    Tzankov, A.
    Heinze, G.
    Raffeld, M. A.
    Pittaluga, S.
    Jaffe, E. S.
    MODERN PATHOLOGY, 2011, 24 : 326A - 327A
  • [9] A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease
    S Tey
    J Butler
    S Durrant
    G Hill
    J Morton
    G Kennedy
    Bone Marrow Transplantation, 2005, 36 : 553 - 554
  • [10] Kinetics of Complete Remission (CR) and CR Duration and Its Impact on Overall Survival (OS) and Event-Free Survival (EFS) in Quantum-First
    Montesinos, Pau
    Perl, Alexander
    Sekeres, Mikkael A.
    Liu, Li
    Kamel, Yasser Mostafa
    Imadalou, Karima
    Schlenk, Richard F.
    Erba, Harry P.
    Dombret, Herve
    BLOOD, 2023, 142
12345